Inventor · disambiguated record
Stephen Jay Kanes
Also filed as: KANES STEPHEN J · KANES STEPHEN JAY
7 granted patents·30 pending applications·54 citations·filing 2013–2025
85Inventor score
Top patents by PatentIndex Score
37 records- 0197US11236121B2Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroidSAGE THERAPEUTICS INC·Filed 2017·Granted Feb 1, 2022·23 cites·5 claims
- 0295US12048706B2Methods of treating epilepsy or status epilepticusSAGE THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·3 cites·4 claims
- 0395US11884696B2Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroidSAGE THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·4 cites·19 claims
- 0494US11554125B2Neuroactive steroids, compositions, and uses thereofSAGE THERAPEUTICS INC·Filed 2021·Granted Jan 17, 2023·8 cites·10 claims
- 0593US10940156B2Neuroactive steroids, compositions, and uses thereofSAGE THERAPEUTICS INC·Filed 2019·Granted Mar 9, 2021·13 cites·10 claims
- 0690US12083131B2Neuroactive steroids, compositions, and uses thereofSAGE THERAPEUTICS INC·Filed 2020·Granted Sep 10, 2024·3 cites·16 claims
- 0785US2025161325A1Methods of treating epilepsy or status epilepticusSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0884US2025304615A1Crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroidSAGE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0981US12358942B2Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroidSAGE THERAPEUTICS INC·Filed 2023·Granted Jul 15, 2025·0 cites·4 claims
- 1079US2025339447A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1177US2025213591A1Neuroactive steroids, compositions, and uses thereofSAGE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1274US2023355639A1Neuroactive steroids, compositions, and uses thereofSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1372US2023201224A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1472US2022323462A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1570US2025387414A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1669US2023310459A1Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1764US2019269699A1Methods of treating epilepsy or status epilepticusSAGE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1862US2025170149A1Neuroactive steroids for treatment of gastrointestinal diseases or conditionsSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1962US2025177418A1Neuroactive steroids for treatment of gastrointestinal diseases or conditionsSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2062US2025170148A1Neuroactive steroids for treatment of gastrointestinal diseases or conditionsSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2162US2025170147A1Neuroactive steroids for treatment of gastrointestinal diseases or conditionsSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2261US2023346801A1Use of agents for treatment of respiratory conditionsSAGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2361US2022110949A1A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2461US2020306265A1Neuroactive steroids, compositions, and uses thereofSAGE THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2561US2023414636A1Use of gabaa modulators for treatment of respiratory conditionsSAGE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2661US2019038639A1Methods of treating epilepsy or status epilepticusSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2759US2020113917A119-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2859US2014057885A1Methods of treating epilepsy or status epilepticusREDDY KIRAN·Filed 2013·Application pending·0 cites
- 2958US2020281943A1Neuroactive steroids and their methods of useSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3058US2021338692A1A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3158US2025295674A1Neuroactive steroids for treatment of cns-related disordersSAGE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3257US2024216396A1Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating femaleSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3354US2024245711A1A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorderSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3454US2024216395A119-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depressionSAGE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3550US2023018765A1A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereofSAGE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3646US2020276209A1Methods of treating epilepsy or status epilepticusSAGE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3744US2017348327A1Neuroactive steroids, compositions, and uses thereofSAGE THERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen Jay Kanes files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →